Last updated: 2026-11-13 13:12:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Candel Therapeutics, Inc. (CADL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5.63, with a market capitalization of $641.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.35 to $14.00. This page covers its latest market performance, valuation, price trends and company information.
$641.99M | |
$5.14 | |
$5.79 | |
$5.05 | |
$8.39 | |
196.26K | |
1.13M | |
-- | |
$14.00 | |
$4.35 | |
-- | |
-- |
Candel Therapeutics, Inc. (CADL) is trading at $5.63 in pre-market trading as of 2026-11-13 13:11:00, down 32.87% ($2.76) from the previous close of $8.39
Pre-market trading shows how investors are pricing CADL before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Candel Therapeutics, Inc. (CADL) moved from $8.04 to $5.63, representing a decline of 29.95% ($2.41).
The stock traded between $5.05 and $9.84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.03 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 13.3%
CADL is currently trading at $5.63, placing it 13.3% of the way from its 52-week low of $4.35 to its 52-week high of $14.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Candel Therapeutics, Inc. and CADL stock.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
Candel Therapeutics shares plunge after-hours following mid-2027 FDA filing plans and wider third-quarter loss.
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.35) by 20 percent. This is a 33.33 percent decrease over losses of $(0.21) per share from
Eligible investors can buy real shares of Candel Therapeutics, Inc. (CADL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CADL, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CADL shares and USD.
CADL Shares to USD
1.00 CADL shares = 5.632 USD
Calculations are estimates based on the latest available price and are for reference only.
